Catalyst Calendar
Scope

Mon, Jul 6, 2026

1 updates
GMAB
1:59 PM

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Media Release COPENHAGEN, Denmark; July 6, 2026 TEPKINLY ® (epcoritamab) plus lenalidomide and rituximab (R 2) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma in the second-line setting, offering a chemotherapy-free option In the Phase 3

genmab.com

Mon, Jun 29, 2026

1 updates
GMAB
4:14 PM

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed/refractory (R/R) diffuse large B-cell

Trial Results • Phase 3Results event Mon, Jun 29, 2026genmab.com

Wed, Jun 17, 2026

1 updates
GMAB
9:14 AM

Genmab A/S has published its Articles of Association

Genmab A/S has published its Articles of Association dated June 16, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T:

genmab.com

Tue, Jun 16, 2026

1 updates
GMAB
3:12 PM

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.

genmab.com

Mon, Jun 15, 2026

2 updates
GMAB
12:04 PM

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of June 12,

genmab.com
GMAB
10:07 AM

Genmab A/S has published its Articles of Association

Genmab A/S has published its Articles of Association dated June 11, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T:

genmab.com

Sat, Jun 13, 2026

1 updates
GMAB
12:45 PM

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE ® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) ineligible for anthracycline-based chemotherapy

Presentation / Abstract • Phase 2EHA poster presentation Thu, Jun 11, 2026genmab.com

Thu, Jun 11, 2026

2 updates
GMAB
10:45 AM

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Media Release COPENHAGEN, Denmark; June 11, 2026 Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE ® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R 2) data across subgroups in this trial of relapsed or refractory (R/R) follicular

Presentation / Abstract • Phase 3EHA oral presentation Thu, Jun 11, 2026genmab.com

Fri, May 29, 2026

1 updates

Thu, May 21, 2026

1 updates
GMAB
5:00 PM

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations Three abstracts will show the ongoing clinical

genmab.com

Wed, May 13, 2026

1 updates
GMAB
9:46 AM

Genmab A/S has published its Articles of Association

Genmab A/S has published its Articles of Association dated May 12, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T:

genmab.com

Tue, May 12, 2026

1 updates
GMAB
1:46 PM

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; May 12, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.

genmab.com

Fri, May 8, 2026

1 updates
GMAB
3:05 PM

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; May 8, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of May 8, 2026,

genmab.com

Thu, May 7, 2026

1 updates
GMAB
11:02 AM

Genmab Announces Financial Results for the First Quarter of 2026

May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025, to $896 million FDA approved an sBLA to remove the recommendation for 24-hour hospitalization for patients with third line

genmab.com

Fri, Apr 17, 2026

2 updates
GMAB
11:59 AM

Genmab A/S has published its Articles of Association

Genmab A/S has published its Articles of Association dated March 19, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

genmab.com
GMAB
10:57 AM

Genmab A/S Share Capital Reduction

Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 19, 2026, it was decided to reduce the Company’s share capital with nominally DKK 1,900,000 by cancellation of 1,900,000 of the Company’s holding of shares with a

genmab.com

Tue, Apr 14, 2026

2 updates
GMAB
10:45 AM

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of April 13, 2026, Orbis

genmab.com